CRU 5002

Blog

In the blog you can regularly read articles on current topics and on new results of the Clinical Research Group KFO 5002.

The Molecular Pancreas Program (MolPAC) introduces itself

The UMG Molecuar Pankreas Program (MolPAC) is a prospective clinical registry for pancreatic cancer patients jointly established by the Department of Gastroenterology, Gastrointestinal Oncology and Endocrinology, the Institute of Pathology, the Clinic of General-, Visceral- and Pediatric Surgery and the Institute of Human Genetics of the UMG.

Why is Pancreatic Cancer Research so Important?

The diagnosis of a malignant disease is always a pivotal incident for the affected person and his or her relatives. Given its extremely dismal prognosis, this is particularly true for the diagnosis of pancreatic ductal adenocarcinoma (PDAC). With approximately 17.000 new cases per year in Germany, PDAC is a relatively rare malignant disease.

CRU 5002: The interdisciplinary team introduces itself

In CRU 5002 we explore the mechanistic, functional and therapeutic implications of subtype-dependent genome dynamic alterations for pancreatic cancer progression and therapy resistance. Our consortium aims to elucidate molecular mechanisms that determine highly clinically relevant problems and to identify therapeutic strategies that improve pancreatic cancer treatment.

1st Virtual Göttingen-Munich-Marburg Pancreatic Cancer Meeting

In order to foster scientific exchange in the pancreatic cancer research community, the three DFG (Deutsche Forschungsgemeinschaft)-funded pancreatic cancer research consortia, the CRU/KFO 5002 from Göttingen, CRC/SFB 1321 from Munich and the CRU/KFO325 from Marburg teamed up and jointly organized the 1st Virtual Göttingen-Munich-Marburg Pancreatic Cancer Meeting.

You may also be interested in

Follow us